JP2023518249A - ヘキソース型単糖およびその類縁体による、ウイルス感染症の処置方法 - Google Patents

ヘキソース型単糖およびその類縁体による、ウイルス感染症の処置方法 Download PDF

Info

Publication number
JP2023518249A
JP2023518249A JP2022555959A JP2022555959A JP2023518249A JP 2023518249 A JP2023518249 A JP 2023518249A JP 2022555959 A JP2022555959 A JP 2022555959A JP 2022555959 A JP2022555959 A JP 2022555959A JP 2023518249 A JP2023518249 A JP 2023518249A
Authority
JP
Japan
Prior art keywords
group
hydrogen
alkyl
independently selected
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022555959A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518249A5 (cg-RX-API-DMAC10.html
Inventor
ウォルデマー プリーベ
イザベラ フォクト
ラファウ ジエリンスキ
スタニスワフ スコラ
ドナルド ピッカー
ワルター クレンプ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Moleculin Biotech Inc
Original Assignee
The University of Texas System
Moleculin Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System, Moleculin Biotech Inc filed Critical The University of Texas System
Publication of JP2023518249A publication Critical patent/JP2023518249A/ja
Publication of JP2023518249A5 publication Critical patent/JP2023518249A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022555959A 2020-03-16 2021-03-16 ヘキソース型単糖およびその類縁体による、ウイルス感染症の処置方法 Pending JP2023518249A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062990337P 2020-03-16 2020-03-16
US62/990,337 2020-03-16
PCT/US2021/022622 WO2021188586A1 (en) 2020-03-16 2021-03-16 Method of treating viral infections with hexose type monosaccharides and analogs thereof

Publications (2)

Publication Number Publication Date
JP2023518249A true JP2023518249A (ja) 2023-04-28
JP2023518249A5 JP2023518249A5 (cg-RX-API-DMAC10.html) 2024-03-19

Family

ID=75439533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555959A Pending JP2023518249A (ja) 2020-03-16 2021-03-16 ヘキソース型単糖およびその類縁体による、ウイルス感染症の処置方法

Country Status (11)

Country Link
US (1) US20230130134A1 (cg-RX-API-DMAC10.html)
EP (1) EP4121060A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023518249A (cg-RX-API-DMAC10.html)
KR (1) KR20220166800A (cg-RX-API-DMAC10.html)
CN (1) CN115515601B (cg-RX-API-DMAC10.html)
AU (1) AU2021239927A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022018536A2 (cg-RX-API-DMAC10.html)
CA (1) CA3170872A1 (cg-RX-API-DMAC10.html)
IL (1) IL296389A (cg-RX-API-DMAC10.html)
MX (1) MX2022011488A (cg-RX-API-DMAC10.html)
WO (1) WO2021188586A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118401539A (zh) 2021-12-15 2024-07-26 兆维生物科技公司 官能化的n-乙酰半乳糖胺类似物
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs
EP4582080A1 (en) 2024-01-02 2025-07-09 G.ST Antivirals GmbH Dispenser for mucosal administration comprising 2-deoxy-glucose or analogues thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505058A (ja) * 2011-01-11 2014-02-27 ザ・ユニバーシティ・オブ・テキサス・エム・ディー・アンダーソン・キャンサー 増殖性および炎症性皮膚疾患の治療用単糖ベース化合物
WO2019149436A1 (en) * 2018-01-30 2019-08-08 Medizinische Universität Wien Medicament for prevention or treatment of rhinovirus infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
ATE544865T1 (de) * 2002-07-12 2012-02-15 Us Gov Health & Human Serv Assays für den zusammenbau von ebola-virus- nukleocapsiden
AU2004204778B2 (en) 2003-01-10 2008-05-22 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
EP1986660A4 (en) * 2006-02-24 2009-08-26 Univ Texas HEXOSE COMPOUNDS FOR CANCER TREATMENT
WO2009108926A1 (en) 2008-02-29 2009-09-03 Board Of Regents, The University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
WO2008131024A1 (en) 2007-04-17 2008-10-30 Board Of Regents, The University Of Texas System Iodo-hexose compounds useful to treat cancer
US8927506B2 (en) 2008-07-11 2015-01-06 Board Of Regents, The University Of Texas System Acetates of 2-deoxy monosaccharides with anticancer activity
US8173636B2 (en) * 2009-04-03 2012-05-08 Achillion Pharmaceuticals, Inc. Hydroxylthienoquinolones and related compounds as anti-infective agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505058A (ja) * 2011-01-11 2014-02-27 ザ・ユニバーシティ・オブ・テキサス・エム・ディー・アンダーソン・キャンサー 増殖性および炎症性皮膚疾患の治療用単糖ベース化合物
WO2019149436A1 (en) * 2018-01-30 2019-08-08 Medizinische Universität Wien Medicament for prevention or treatment of rhinovirus infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CELL METABOLISM, vol. 32, JPN6026030215, September 2020 (2020-09-01), pages 437 - 446, ISSN: 0005908276 *
PNAS, vol. 115(30), JPN6025005710, 2018, pages 7158 - 7165, ISSN: 0005908275 *

Also Published As

Publication number Publication date
CN115515601A (zh) 2022-12-23
CN115515601B (zh) 2026-06-16
IL296389A (en) 2022-11-01
AU2021239927A1 (en) 2022-10-06
MX2022011488A (es) 2023-03-01
EP4121060A1 (en) 2023-01-25
KR20220166800A (ko) 2022-12-19
BR112022018536A2 (pt) 2022-11-29
US20230130134A1 (en) 2023-04-27
WO2021188586A1 (en) 2021-09-23
CA3170872A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
JP3548194B2 (ja) 過度のコラーゲン破壊を防止する薬剤
US20120276108A1 (en) Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
US20230130134A1 (en) Method of treating viral infections with hexose type monosaccharides and analogs thereof
US20110275577A1 (en) Methods of treating dermatologic, gynecologic, and genital disorders with caffeic acid analogs
EP2909216B1 (en) Compositions and methods for improving glucose uptake
US20210322396A1 (en) Compositions with synergistic permeation enhancers for drug delivery
US11925654B2 (en) Esters of 2-deoxy-monosaccharides with anti proliferative activity
JP6408489B2 (ja) 治療配合物（ｃｏｍｐｏｕｎｄｓ）
EP3134417B1 (en) Small molecule analogs of e4orf1
WO2022031577A1 (en) Thermo-sensitive permeation enhancing formulations for drug delivery
JP2001270826A (ja) 皮膚疾患治療・予防用外用剤
JP2812757B2 (ja) インビボでアロマターゼを阻害する５α―ジヒドロ―１９―ノルエチステロン及びその誘導体を含有する組成物
HK1214267B (en) Compositions and methods for improving glucose uptake
JP2001288082A (ja) 乾癬治療・予防用外用剤
WO2009047481A1 (en) Method & composition for the treatment of acne and sebum dependent pilosebaceous disorders
HK1235406A1 (en) Small molecule analogs of e4orf1
HK1235406B (en) Small molecule analogs of e4orf1
JPWO1990010640A1 (ja) インビボでアロマターゼを阻害する５α―ジヒドロ―１９―ノルエチステロン及びその誘導体を含有する組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221125

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240308

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250808

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260424

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260701